Ayman Iskander
St. Joseph Hospital
9 Papers
13 Citations
Ayman Iskander is an academic researcher from St. Joseph Hospital. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 4, co-authored 5 publications.
Chat about Author
Papers
Wire-Interwoven Nitinol Stent Outcome in the Superficial Femoral and Proximal Popliteal Arteries: Twelve-Month Results of the SUPERB Trial
Lawrence A. Garcia,Michael R. Jaff,Christopher Metzger,Gino Sedillo,Ashish Pershad,Frank Zidar,Raghotham R. Patlola,Robert G. Wilkins,Andrey Espinoza,Ayman Iskander,George S. Khammar,Yazan Khatib,Robert Beasley,Satyaprakash Makam,Richard Kovach,Suraj Kamat,Luis R. Leon,William Britton Eaves,Jeffrey J. Popma,Laura Mauri,Dennis Donohoe,Carol C. Base,Kenneth Rosenfield +22 more
TL;DR: The SUPERB Trial, an investigational device exemption study using an interwoven nitinol wire stent in the femoropopliteal artery, achieved the efficacy and safety performance goals predesignated by the Food and Drug Administration.
147
2-Year Outcomes After Transcatheter Versus Surgical Aortic Valve Replacement in Low-Risk Patients.
John K. Forrest,G. Michael Deeb,Steven J. Yakubov,Joshua Rovin,Mubashir Mumtaz,Hemal Gada,Daniel O'Hair,Tanvir Bajwa,Paul Sorajja,John Heiser,William Merhi,Abeel A. Mangi,Douglas Spriggs,Neal S. Kleiman,Stanley Chetcuti,Paul S. Teirstein,George L. Zorn,Peter Tadros,Didier Tchetche,Jon R. Resar,Antony Walton,Thomas G. Gleason,Basel Ramlawi,Ayman Iskander,R. Caputo,Jae K. Oh,Jian Huang,Michael J. Reardon +27 more
TL;DR: The Evolut Low Risk Trial as mentioned in this paper showed that transcatheter aortic valve replacement (TAVR) with a supra-annular, self-expanding valve was noninferior to surgery for the primary endpoint of all-cause mortality or disabling stroke at 2 years.
72
Prospective Multicenter Trial of Pharmacomechanical-Catheter-Directed Thrombolysis with the Bashir Endovascular Catheter for Acute Pulmonary Embolism.
Riyaz Bashir,Malcolm T. Foster,Ayman Iskander,Amir Darki,Wissam Jaber,Parth Rali,Vladimir Lakhter,Ripal T. Gandhi,Andrew S. Klein,Rohit Bhatheja,C Ross,Kannan Natarajan,Aravinda Nanjundappa,John F. Angle,Kenneth Ouriel,Nancy Amoroso,Brian G. Firth,Anthony J. Comerota,Gregory Piazza,Kenneth Rosenfield,Akhilesh K. Sista +20 more
TL;DR: In this paper , the authors evaluated the efficacy and safety of tPA infused using a pharmacomechanical (PM) CDT device called the Bashir endovascular catheter in patients with intermediate-risk acute pulmonary embolism (PE).
45
Balloon- Versus Self-Expanding Valve Systems for Treating Small Failed Surgical Aortic Bioprostheses: The LYTEN Trial.
Josep Rodés-Cabau,Amr E. Abbas,Vicenç Serra,Victoria Vilalta,Luis Nombela-Franco,Ander Regueiro,Karim Al-Azizi,Ayman Iskander,Lenard Conradi,Jessica Forcillo,Scott Lilly,Álvaro Calabuig,Eduard Fernandez-Nofrerias,Siamak Mohammadi,Vassili Panagides,Emilie Pelletier-Beaumont,Philippe Pibarot +16 more
TL;DR: In this paper , the authors compared the hemodynamic results between balloon-expandable valve (BEV) SAPIEN (3/ULTRA, Edwards Lifesciences) and self-expanding valve (SEV) Evolut (R/PRO/PRO+, Medtronic) in ViV-TAVR.
43
Smoking abstinence 1 year after acute coronary syndrome: follow-up from a randomized controlled trial of varenicline in patients admitted to hospital.
Sarah B. Windle,Payam Dehghani,Nathalie Roy,Wayne Old,Francois R. Grondin,Iqbal Bata,Ayman Iskander,Claude Lauzon,Nalin Srivastava,Adam Clarke,Daniel Cassavar,Danielle Dion,Herbert Haught,Shamir R. Mehta,Jean-François Baril,Charles R. Lambert,Mina Madan,Beth L. Abramson,Mark J. Eisenberg +18 more
TL;DR: Varenicline was efficacious for smoking cessation in this high-risk patient population of patients admitted to hospital with acute coronary syndrome, but 60% of patients who received treatment with varenic line still returned to smoking.